

Carmen Ghilardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3849821/publications.pdf>

Version: 2024-02-01

18
papers

620
citations

623734

14
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1291
citing authors

#	ARTICLE	IF	CITATIONS
1	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 555-567.	4.1	11
2	PGC1 α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. <i>Cancer Research</i> , 2022, 82, 1423-1434.	0.9	14
3	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. <i>Journal of Hematology and Oncology</i> , 2021, 14, 186.	17.0	27
4	A novel LICAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. <i>ELife</i> , 2019, 8, .	6.0	38
5	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. <i>Angiogenesis</i> , 2017, 20, 233-241.	7.2	22
6	Thrombospondin $\alpha 1$ is part of a Slug α -independent motility and metastatic program in cutaneous melanoma, in association with α VEGFR $\beta 1$ and α FGF $\beta 2$. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 73-81.	3.3	45
7	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. <i>Oncotarget</i> , 2015, 6, 3043-3054.	1.8	38
8	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. <i>Oncotarget</i> , 2015, 6, 28389-28400.	1.8	13
9	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. <i>Cancer Research</i> , 2014, 74, 6980-6990.	0.9	110
10	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. <i>Neoplasia</i> , 2012, 14, 846-856.	5.3	28
11	Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1167-1178.	5.4	40
12	Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. <i>Clinical and Experimental Metastasis</i> , 2010, 27, 43-53.	3.3	18
13	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. <i>Endocrinology</i> , 2010, 151, 4643-4653.	2.8	15
14	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. <i>BMC Genomics</i> , 2008, 9, 201.	2.8	56
15	Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 111-21.	4.1	46
16	Anticancer Therapy with Angiogenesis Inhibitors. <i>Tumori</i> , 2001, 87, 14-16.	1.1	1
17	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001, 20, 7293-7300.	5.9	51
18	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. <i>Experimental Cell Research</i> , 2000, 258, 384-394.	2.6	43